Viralytics (OTCMKTS: VRACY) is one of 32 publicly-traded companies in the “Commercial physical research” industry, but how does it compare to its peers? We will compare Viralytics to related companies based on the strength of its institutional ownership, valuation, analyst recommendations, earnings, profitability, dividends and risk.


This table compares Viralytics and its peers’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Viralytics N/A N/A N/A
Viralytics Competitors -261.93% -63.97% -23.41%

Volatility and Risk

Viralytics has a beta of -6.1, meaning that its stock price is 710% less volatile than the S&P 500. Comparatively, Viralytics’ peers have a beta of 3.22, meaning that their average stock price is 222% more volatile than the S&P 500.

Institutional & Insider Ownership

46.4% of shares of all “Commercial physical research” companies are held by institutional investors. 16.3% of shares of all “Commercial physical research” companies are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Analyst Recommendations

This is a summary of recent recommendations and price targets for Viralytics and its peers, as provided by

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Viralytics 0 0 0 0 N/A
Viralytics Competitors 94 516 1219 42 2.65

As a group, “Commercial physical research” companies have a potential upside of 10.50%. Given Viralytics’ peers higher probable upside, analysts plainly believe Viralytics has less favorable growth aspects than its peers.

Valuation & Earnings

This table compares Viralytics and its peers revenue, earnings per share (EPS) and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Viralytics $4.88 million -$9.26 million -32.00
Viralytics Competitors $806.43 million $48.21 million 11.39

Viralytics’ peers have higher revenue and earnings than Viralytics. Viralytics is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.


Viralytics peers beat Viralytics on 7 of the 10 factors compared.

Viralytics Company Profile

Viralytics Limited, a biotechnology company, focuses on the development and commercialization of oncolytic immunotherapies in Australia and internationally. The company's lead investigational product is CAVATAK, a proprietary formulation of an oncolytic common cold virus that is in Phase Ib clinical trials for the treatment of melanoma, and lung and bladder cancer; Phase II clinical trials for the treatment of late stage melanoma; and in pre-clinical studies for the treatment of prostate and breast cancer, multiple myeloma, pancreatic cancer, malignant glioma, acute myeloid leukemia, and chronic lymphocytic leukemia. It is also developing EVATAK to treat ovarian, prostate, and gastric cancer. The company was formerly known as Psiron Ltd. and changed its name to Viralytics Limited in December 2006. Viralytics Limited is headquartered in Sydney, Australia.

Receive News & Ratings for Viralytics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Viralytics and related companies with's FREE daily email newsletter.